DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Allergic Conjunctivitis Pipeline Highlights - 2017" drug pipelines to their offering.
Allergic Conjunctivitis Pipeline Highlights - 2017, provides most up-to-date information on key pipeline products in the global Allergic Conjunctivitis market. It covers emerging therapies for Allergic Conjunctivitis in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages:
The report provides Allergic Conjunctivitis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Allergic Conjunctivitis pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.
The report provides Allergic Conjunctivitis pipeline products by the company.
Short-term Launch Highlights:
Find out which Allergic Conjunctivitis pipeline products will be launched in the US and Ex-US till 2020.
Key Topics Covered:
1. Allergic Conjunctivitis Pipeline by Stages
2. Allergic Conjunctivitis Pipeline by Drug Class
3. Allergic Conjunctivitis Pipeline by Company
4. Allergic Conjunctivitis Phase 3 Clinical Trial Insights
5. Allergic Conjunctivitis Phase 2 Clinical Trial Insights
6. Allergic Conjunctivitis Phase 1 Clinical Trial Insights
7. Allergic Conjunctivitis Preclinical Research Insights
8. Allergic Conjunctivitis Discovery Stage Insights
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/qkp64r/allergic